Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. [artículo]
Por: López Muñoz, Francisco [Instituto de Investigación i+12]
.
Colaborador(es): Instituto de Investigación imas12.
Tipo de material: 
ArtículoEditor: Frontiers in aging neuroscience, 2016Descripción: 9:159.Recursos en línea: Acceso libre | Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC17998 (Navegar estantería) | Disponible |
Formato Vancouver:
Romero A, Ramos E, Patiño P, Oset Gasque MJ, López Muñoz F, Marco Contelles J et al. Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Front Aging Neurosci. 2016 Nov 23;8:281. doi: 10.3389/fnagi.2016.00281. Erratum in: Front Aging Neurosci. 2017 May 29;9:159.
PMID: 27932976
PMC5120103
Contiene 102 referencias
Corrigendum: Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.
PMID: 28572769
Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this Perspective article, an update on the specific results of the melatonin and several new nitrones are presented.
No hay comentarios para este ejemplar.